脊髓小脑共济失调1、2、3和6型患者的生存情况(EUROSCA):一项纵向队列研究
EUROSCA纵向队列研究纳入欧洲17个共济失调转诊中心的525例SCA1、SCA2、SCA3或SCA6患者,分析其总体生存及影响因素。SCA1、SCA2、SCA3、SCA6的10年生存率分别为57%、74%、73%、87%,吞咽困难、SARA评分、起病年龄、CAG重复长度及肌张力障碍等为各型生存的预测因素。
要点
- SCA1、SCA2、SCA3、SCA6的10年生存率分别为57%、74%、73%、87%。
- SCA1中吞咽困难与生存期缩短相关(HR 4.52)。
- SCA2、SCA3、SCA6中SARA评分较高均与生存期缩短相关。
核心结论
- 研究基于长期随访提供了常见脊髓小脑共济失调患者的生存定量数据,预后生存列线图或有助于未来干预研究的患者选择和分层,但研究结果需在外部人群中验证后方可用于患者及家属咨询。
研究设计与样本
- 纵向队列研究(EUROSCA),纳入欧洲10个国家17个共济失调转诊中心的18岁及以上男性和女性,经基因检测确诊为SCA1、SCA2、SCA3或SCA6且为进行性、其他原因不能解释的共济失调患者,共525例。
主要发现
- 2005年7月1日至2006年8月31日纳入SCA1(n=117)、SCA2(n=162)、SCA3(n=139)、SCA6(n=107)患者并随访。
- 10年生存率:SCA1为57%(95% CI 47-69),SCA2为74%(67-81),SCA3为73%(65-82),SCA6为87%(80-94)。
- SCA1中与较短生存相关的因素:吞咽困难(HR 4.52,95% CI 1.83-11.15)和较高的SARA评分(HR 1.26,1.19-1.33)。
- SCA2中与较短生存相关的因素:入组时年龄较大(HR 1.04,1.01-1.08)、CAG重复长度较长(HR 1.16,1.03-1.31)和较高的SARA评分(HR 1.15,1.10-1.20)。
- SCA3中与较短生存相关的因素:入组时年龄较大(HR 1.44,1.20-1.74)、肌张力障碍(HR 2.65,1.21-5.53)、较高的SARA评分(HR 1.26,1.17-1.35)及CAG与入组年龄间的负交互作用(HR 0.994,0.991-0.997);SCA6中较高的SARA评分(HR 1.17,1.08-1.27)与较短生存相关。
关键数值与推荐
- 列线图预测10年生存概率的区分度:c指数SCA1为0.905(SD 0.027),SCA2为0.822(0.032),SCA3为0.891(0.021),SCA6为0.825(0.054)。
临床怎么用
- 作者认为,预后生存列线图或有助于未来干预研究中患者的选择和分层。
- 作者指出,研究结果需在外部人群中验证后方可用于患者及家属咨询。
局限性
- 研究结果需在外部人群中验证后方可用于患者及家属咨询。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Spinocerebellar ataxias are dominantly inherited progressive ataxia disorders that can lead to premature death. We aimed to study the overall survival of patients with the most common spinocerebellar ataxias (SCA1, SCA2, SCA3, and SCA6) and to identify the strongest contributing predictors that affect survival. METHODS: In this longitudinal cohort study (EUROSCA), we enrolled men and women, aged 18 years or older, from 17 ataxia referral centres in ten European countries; participants had positive genetic test results for SCA1, SCA2, SCA3, or SCA6 and progressive, otherwise unexplained, ataxias. Survival was defined as the time from enrolment to death for any reason. We used the Cox regression model adjusted for age at baseline to analyse survival. We used prognostic factors with a p value less than 0·05 from a multivariate model to build nomograms and assessed their performance based on discrimination and calibration. The EUROSCA study is registered with ClinicalTrials.gov, number NCT02440763. FINDINGS: Between July 1, 2005, and Aug 31, 2006, 525 patients with SCA1 (n=117), SCA2 (n=162), SCA3 (n=139), or SCA6 (n=107) were enrolled and followed up. The 10-year survival rate was 57% (95% CI 47-69) for SCA1, 74% (67-81) for SCA2, 73% (65-82) for SCA3, and 87% (80-94) for SCA6. Factors associated with shorter survival were: dysphagia (hazard ratio 4·52, 95% CI 1·83-11·15) and a higher value for the Scale for the Assessment and Rating of Ataxia (SARA) score (1·26, 1·19-1·33) for patients with SCA1; older age at inclusion (1·04, 1·01-1·08), longer CAG repeat length (1·16, 1·03-1·31), and higher SARA score (1·15, 1·10-1·20) for patients with SCA2; older age at inclusion (1·44, 1·20-1·74), dystonia (2·65, 1·21-5·53), higher SARA score (1·26, 1·17-1·35), and negative interaction between CAG and age at inclusion (0·994, 0·991-0·997) for patients with SCA3; and higher SARA score (1·17, 1·08-1·27) for patients with SCA6. The nomogram-predicted probability of 10-year survival showed good discrimination (c index 0·905 [SD 0·027] for SCA1, 0·822 [0·032] for SCA2, 0·891 [0·021] for SCA3, and 0·825 [0·054] for SCA6). INTERPRETATION: Our study provides quantitative data on the survival of patients with the most common spinocerebellar ataxias, based on a long follow-up period. These results have implications for the design of future interventional studies of spinocerebellar ataxias; for example, the prognostic survival nomogram could be useful for selection and stratification of patients. Our findings need validation in an external population before they can be used to counsel patients and their families. FUNDING: European Union 6th Framework programme, German Ministry of Education and Research, Polish Ministry of Scientific Research and Information Technology, European Union 7th Framework programme, and Fondation pour la Recherche Médicale.
引用
- Diallo A, Jacobi H, Cook A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol. 2018. PMID: 29553382. doi:10.1016/S1474-4422(18)30042-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。